QNBC treatment with ADRM1 inhibitor Up284
Official title: Augmenting Quadruple Negative Breast Cancer Treatment by ADRM1 Inhibitor Up284
Funded at Tuskegee University · NIH-11367924 · Data updated 2026-11-12
A new drug approach targets ADRM1 with Up284 to help people with quadruple-negative breast cancer, aiming to improve outcomes and find biomarkers to guide therapy.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Tuskegee University NIH-funded |
| Lab location | 1 site (Tuskegee Institute, United States) |
| Project start | July 7, 1997 |
| Project end | March 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $357,961 |
| NIH project number | 5U54MD007585-35 |
| Project ID | NIH-11367924 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with quadruple-negative breast cancer, particularly African American patients, who could be tested for ADRM1 biomarker status to determine eligibility for Up284 therapy.
✕Less likely to help
Patients whose tumors do not express the ADRM1 biomarker or who cannot tolerate ADRM1 inhibitors may not benefit from this approach.
What this research studies
This project aims to use Up284, an ADRM1 inhibitor, as the lead therapy for quadruple-negative breast cancer (QNBC) and to identify biomarkers that tell doctors which QNBC patients are most likely to benefit. The team will explore how Up284 works in QNBC and how best to monitor safety and effectiveness. Researchers plan to study patient samples and tumor characteristics to develop a biomarker-based approach for selecting eligible patients. Given the higher risk and poorer outcomes in African American women with QNBC, the study also focuses on reducing disparities in care and outcomes.
Why it matters
Potential benefit: If successful, patients with QNBC could receive a targeted therapy with biomarker-guided selection, potentially improving survival and quality of life.
How similar studies have gone: Proteasome inhibitors have shown limited success in solid tumors, so this approach is exploratory but builds on existing biomarker and ADRM1 protein research.
Where this research is happening
-
Tuskegee University
Tuskegee Institute, United States Active
Researchers
- Principal investigator: Karanam, Balasubramanyam — Tuskegee University
- Study coordinator: Karanam, Balasubramanyam
Related research
Other NIH-funded projects on the same topics.
-
Improving Breast Cancer Guideline Adherence in Nigeria
Aimed at helping doctors in Nigeria follow international guideline-based breast cancer care to improve outcomes for women with breast cancer.
-
Genomic study to understand how genetics and epigenetics shape triple-negative breast cancer in African ancestry
This study looks at how inherited genes and gene activity affect triple-negative breast cancer in people of African ancestry to better understand why outcomes can be worse.
-
Translational breast cancer research to improve treatment options
A comprehensive program at Baylor College of Medicine is focusing on breast cancer; researchers will advance targeted therapies and biomarkers to help patients with aggressive or hard-to-treat forms.
-
Cancer Pain Management for Asian American Breast Cancer Survivors with Depressive Symptoms
A technology-based program helps Asian American breast cancer survivors with depressive symptoms manage chronic pain more effectively from home using a web app and mobile tools.
-
Co-Targeting IL-6 and CDK4/6 to Prevent TNBC in Women Veterans
A study aims to block two cancer-promoting pathways (IL-6 and CDK4/6) to prevent or reduce progression of triple-negative breast cancer in women veterans.
-
Gut bacteria and metabolites linked to breast density and cancer risk
A small, patient-friendly study will explore whether gut bacteria and their byproducts are connected to high breast density, which can raise cancer risk and make screening less accurate.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.